US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Roche Holding Ltd

41.07

-0.2560-0.62%

Volume:1.58M

Turnover:64.76M

Market Cap:265.91B

PE:26.48

High:41.34

Open:41.32

Low:41.01

Close:41.33

Loading ...

Overview Company News Filings

Pharma Stocks Drop After Trump Threatens Tariffs on Medicines -- WSJ

Roche's Eye Drug in Focus for 1Q Earnings -- Market Talk

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

Trump teases targeted tariffs on overseas drug manufacturers

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

Roche to Launch Late-Stage Trial for Alzheimer's Drug Candidate After Positive Study Results

EMA put clinical hold on Roche, Sarepta DMD studies after death

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

Big Pharma Avoids Worst-Case Tariff Scenario -- WSJ

Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug

Roche Poised For Growth Amid Obesity-Drug Ambitions -- Market Talk

The Zacks Analyst Blog Roche Holding, Comcast, Eaton Corp and National Presto Industries

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion

Novartis Reports Updated Positive Data From Phase III SMA Program

SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion

Trump’s DEI Battle Goes Global as Swiss Drugs Group Roche (RHHBY) Terminates Targets

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RHHBY/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"Roche Holding Ltd","latestPrice":41.074,"timestamp":1746548940000,"preClose":41.33,"halted":0,"volume":1575417,"delay":15,"floatShares":6374000000,"shares":6474029800,"eps":1.550894,"marketStatus":"Trading","change":-0.256,"latestTime":"05-06 12:29:00 EDT Delay","open":41.32,"high":41.34,"low":41.0075,"amount":64755225.128682,"amplitude":0.008045,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746561600000},"marketStatusCode":2,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":41.33,"volumeRatio":1.352998},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6374000000,"roa":"12.75%","roe":"26.47%","lyrEps":2.136203,"volumeRatio":1.352998,"shares":6474029800,"dividePrice":1.471756,"high":41.34,"amplitude":0.008045,"preClose":41.33,"low":41.0075,"week52Low":30.03,"pbRate":"6.90","psRate":"3.51","week52High":44.31,"institutionHeld":0,"latestPrice":41.074,"eps":1.550894,"divideRate":0.035832,"volume":1575417,"delay":15,"ttmEps":1.550894,"open":41.32,"prevYearClose":34.88,"prevWeekClose":41.08,"prevMonthClose":40.77,"prevQuarterClose":41.15,"fiveDayClose":40.66,"twentyDayClose":36,"sixtyDayClose":39.77},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526356596","title":"Pharma Stocks Drop After Trump Threatens Tariffs on Medicines -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2526356596","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526356596?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:17","pubTimestamp":1744193820,"startTime":"0","endTime":"0","summary":"Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil.-- Switzerland's Roche and Novartis, the U.K.'s AstraZeneca and GSK and France's Sanofi were all down 5% or more in European midday trade.-- Japan's Daiichi Sankyo and Takeda Pharmaceutical closed 6% and 4.7% lower, respectively.-- In U.S. premarket trading, Eli Lilly, Merck and Pfizer all fell at least 1%.The drug sector was spared from Trump's sweeping tariff plan that kicked in today, but the president's remarks at a Tuesday dinner with House Republicans suggested levies could come very shortly.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2417539215.USD","03165","LU2236285917.USD","SG9999003800.SGD","LU1894683348.USD","SG9999002232.USD","LU0070302665.USD","LU0058720904.USD","IE00B4R5TH58.HKD","IE0002270589.USD","GSK.UK","IE00B19Z3581.USD","LU0289739699.SGD","SG9999001176.USD","IE00B19Z3B42.SGD","BK4588","LU0170899867.USD","BK4007","IE00BJJMRZ35.SGD","LU1066053197.SGD","LU0225284248.USD","LU1023059063.AUD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00BFXG1179.USD","LU2456880835.USD","BK4534","SG9999013999.USD","LU2462157665.USD","GSK","MDCO","SNY","LU0234572021.USD","BK4599","LU0208291251.USD","LU0889565916.HKD","RHHBY","AZN","BK4532","LU1829250122.USD","BK4533","NVS","LU1894683264.USD","SG9999011175.SGD","BK4568","IE00BLSP4239.USD","LU0321505868.SGD","LU0225771236.USD","IE0009355771.USD"],"gpt_icon":1},{"id":"2526681355","title":"Roche's Eye Drug in Focus for 1Q Earnings -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2526681355","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526681355?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:03","pubTimestamp":1744192980,"startTime":"0","endTime":"0","summary":"1003 GMT - Roche's sales performance of its eye drug Vabysmo will be closely watched among its 1Q results, Barclays analysts say in a note. They anticipate a U.S. sales slowdown due to potential Medicare funding issues affecting Vabysmo patients. While Roche has outperformed its European peers in the large-cap pharmaceutical sector this year, recent disappointing trial results with its multiple sclerosis drug HD Ocrevus and safety worries regarding its Elevidys treatment for Duchenne Muscular Dystrophy have created headwinds. Barclays expects Roche to reaffirm its full-year guidance, and developments around its experimental oral weight-loss drug orforglipron to move the share price more than its 1Q results. Roche shares fall 6% to 234.80 Swiss francs. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY"],"gpt_icon":0},{"id":"2526133062","title":"Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2526133062","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526133062?lang=en_us&edition=fundamental","pubTime":"2025-04-09 17:24","pubTimestamp":1744190640,"startTime":"0","endTime":"0","summary":"Pharmaceutical stocks took a hit after U.S. President Trump said tariffs on pharma imports will be unveiled very shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil globally.In European morning trade, the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--was down 4.5%, against a 2.7% fall for the broader Stoxx Europe 600. The falls mirrored a selloff among pharma stocks in Asia.Switzerland's Roche and Novartis, the U.K.'s AstraZeneca and GSK and France's Sanofi were down 5% or more in morning trade. Japan's Daiichi Sankyo and Takeda Pharmaceutical closed 6% and 4.7% lower, while Australia's CSL shed 5%.The pharma sector was spared from Trump's sweeping tariff plan last week, which kicked in on Wednesday, but the U.S. president had previously pledged to impose tariff on pharma products and his remarks at a Tuesday dinner with House Republicans suggested levies could come soon.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965508806.USD","SG9999017495.SGD","03165","LU0471298694.HKD","LU1934455277.USD","NVS","LU1988902786.USD","SG9999015986.USD","BK4559","LU1732799900.SGD","LU0203201768.USD","LU1720051108.HKD","SG9999013999.USD","LU0965509283.SGD","IE0009355771.USD","LU2133065610.SGD","LU1366192091.USD","BK4581","SG9999014567.USD","LU0289739699.SGD","MDCO","MRK","RHHBY","LU0061475181.USD","LU1718418525.SGD","CSL.AU","GSK.UK","IE00BDGV0183.EUR","BK4007","LU0965509101.SGD","SGXZ99366536.SGD","LU1868836591.USD","PFE","LU1551013342.USD","GSK","SG9999014575.USD","LLY","ABBV","LU1093756168.USD","LU2129689605.HKD","SG9999002224.SGD","LU0320765059.SGD","LU2237443978.SGD","TAK","LU1035773651.USD","LU0417517546.SGD","DSNKY","LU2264538146.SGD","LU1989771016.USD","LU0079474960.USD"],"gpt_icon":1},{"id":"2526382960","title":"Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2526382960","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526382960?lang=en_us&edition=fundamental","pubTime":"2025-04-09 15:23","pubTimestamp":1744183380,"startTime":"0","endTime":"0","summary":"0723 GMT - Pharma stocks take a hit in early morning European trade after U.S. President Trump said at a Tuesday dinner with House Republicans that tariffs on pharmaceuticals will be imposed very shortly. British AstraZeneca and GSK slump 3.9% and 2.8%, respectively. Swiss Roche and Novartis fall 4.8% and 4.1%, respectively. French Sanofi is down 4.5%. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0208291251.USD","BK4007","LU0211331839.USD","LU0320765489.SGD","LU0070302665.USD","RHHBY","LU2456880835.USD","IE00B2B36J28.USD","AZN","LU2236285917.USD","IE0002141913.USD","LU1829250122.USD","BK4578","LU0320765992.SGD","BK4588","IE00B4R5TH58.HKD","BK4568","LU2462157665.USD","BK4532","IE00BFTCPJ56.SGD","03165","LU0109394709.USD","NVS","IE00BJT1NW94.SGD","LU2417539215.USD","LU0889565916.HKD","GSK","IE0009355771.USD","GSK.UK","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2526580918","title":"Trump teases targeted tariffs on overseas drug manufacturers","url":"https://stock-news.laohu8.com/highlight/detail?id=2526580918","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526580918?lang=en_us&edition=fundamental","pubTime":"2025-04-09 11:32","pubTimestamp":1744169520,"startTime":"0","endTime":"0","summary":"'We're going to be announcing, very shortly, a major tariff on pharmaceuticals,' he tells attendees of a Republican fundraising dinner. With the next set of White House-imposed tariffs just hours away from taking effect - including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. - President Donald Trump indicated he intends to roll out more product-specific tariffs down the road.The Republican president has previously threatened import taxes on goods like copper, lumber and pharmaceutical drugs - all of which are currently exempt from Trump's \"reciprocal\" levies.Speaking Tuesday evening at a Republican National Congressional Committee dinner, Trump called out one particular industry in his crosshairs: pharmaceuticals XPH PJP IHE.Trump boasted at the NRCC event, an important venue for fundraising by House Republicans, that he was about to impart \"breaking news.\". Trump went on to observe that the U.S. no longer produces many of the p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS","IHE","LU1829250122.USD","LU0889565916.HKD","AZN","03165","LU0109394709.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BFXG1179.USD","LU1992135399.USD","GSK","LU2462157665.USD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0208291251.USD","LU2272731865.HKD","BK4578","LU2473716301.USD","LU2322448791.USD","BK4568","LU2272731782.SGD","LU2417539215.USD","IE0002141913.USD","LU2322448957.HKD","LU0070302665.USD","IE00B5TLWC47.USD","LU0320765489.SGD","SNY","LU2272731600.USD","XPH","PJP","LU1992135472.HKD","BK4585","RHHBY","IE0009355771.USD","LU2456880835.USD","BK4007","LU2236285917.USD","BK4532","BK4588","GSK.UK","LU0211331839.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2524420475","title":"SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524420475","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524420475?lang=en_us&edition=fundamental","pubTime":"2025-04-04 19:29","pubTimestamp":1743766140,"startTime":"0","endTime":"0","summary":"Shares of Sarepta Therapeutics SRPT dropped more than 6% yesterday after the EMA placed a clinical hold on all studies evaluating Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy . The therapy has been developed in collaboration with pharma giant Roche RHHBY.This hold has been placed in response to a patient’s death post-treatment with Elevidys, which was reported last month. Though the death was due to acute liver failure , Sarepta believes that the patient’s recent CMV infection might have contributed to the outcome. Investigation is still ongoing.In a letter to the World Duchenne Organization, Roche mentioned that the companies are pausing enrollment and dosing of study participants in three studies evaluating the therapy at the EU study sites. This hold will remain ‘until the analysis into the cause of death is complete.’。SRPT and RHHBY entered into a licensing agreement in 2019 to develop Elevidys. Per the agreement, Sarepta retains the rights to market the gene","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-stock-down-ema-places-112900759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ANIP","IE00BFTCPJ56.SGD","RHHBY","SRPT","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","03165","CTMX","IE0009355771.USD","IE00B2B36J28.USD","BK4585","BK4139","IE0002141913.USD"],"gpt_icon":0},{"id":"2524883250","title":"Roche to Launch Late-Stage Trial for Alzheimer's Drug Candidate After Positive Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524883250","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524883250?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:30","pubTimestamp":1743687000,"startTime":"0","endTime":"0","summary":"Roche Holding said it will initiate a late-stage trial for its Alzheimer's drug candidate trontinemab later this year after its mid-stage study showed positive results.The Swiss pharma giant said Thursday during a conference that its experimental treatment showed a reduction of amyloid plaques--protein clumps in the brain that contribute to the disease's progression--in patients with Alzheimer's disease.In addition, its plasma diagnostics test Elecsys pTau181 demonstrated the ability to determine whether or not someone has amyloid pathology, one of the hallmarks of Alzheimer's disease.\"We are pleased with the progress across our Alzheimer's portfolio as we move ahead with a Phase III trontinemab program and continue to expand our diagnostic solutions,\" Levi Garraway, Roche's Chief Medical Officer said.More than 55 million people worldwide are living with dementia, of which around 70% have Alzheimer's. Up to three-quarters of people experiencing symptoms of Alzheimer's remain undiagnose","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","RHHBY","BK4007","SSI"],"gpt_icon":0},{"id":"2524254274","title":"EMA put clinical hold on Roche, Sarepta DMD studies after death","url":"https://stock-news.laohu8.com/highlight/detail?id=2524254274","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524254274?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:55","pubTimestamp":1743684934,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) sent a letter dated March 31 to the World Duchenne Organization stating the European Medicines Agency requested a temporary clinical ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ema-put-clinical-hold-on-roche-sarepta-dmd-studies-after-death?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ema-put-clinical-hold-on-roche-sarepta-dmd-studies-after-death?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03165","RHHBY","BK4007"],"gpt_icon":0},{"id":"2524284993","title":"Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2524284993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524284993?lang=en_us&edition=fundamental","pubTime":"2025-04-03 16:41","pubTimestamp":1743669660,"startTime":"0","endTime":"0","summary":"0841 GMT - Uncertainty remains across the pharmaceutical industry until there is better visibility around the potential impact of U.S. tariffs, Shore Capital analyst Sean Conroy says in a note. U.S. President Trump announced across-the-board 10% tariffs on Wednesday on all imports and a 20% tariff on EU goods which, for now, exempts pharmaceuticals. GSK confirmed that there would be no changes to its outlook, whereas AstraZeneca said it will assess the implications of Trump's tariff announcement and Roche said it would consider additional U.S. investments. Shore Capital anticipates that stock prices might remain weak until companies can quantify the potential impact of tariffs on earnings and revenue, Conroy says.  GSK's shares are up 1.5%, while AstraZeneca's are up 1.6% and Roche's are down 2.1%. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","GSK.UK","LU2236285917.USD","LU2462157665.USD","BK4532","BK4588","AZN","03165","BK4007","GSK","LU0320765992.SGD","LU1829250122.USD","LU2456880835.USD","BK4568","BK4585","LU0109394709.USD","LU2417539215.USD","RHHBY"],"gpt_icon":0},{"id":"2524832162","title":"Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2524832162","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524832162?lang=en_us&edition=fundamental","pubTime":"2025-04-03 15:51","pubTimestamp":1743666660,"startTime":"0","endTime":"0","summary":"0751 GMT - Big Pharma stocks are up after U.S. President Trump exempted pharmaceuticals for now from his reciprocal tariffs on global imports. \"It is still somewhat unclear whether the broader reaching 10% baseline tariffs could still be levied against imported drugs and vaccines, in our view,\" Shore Capital analyst Sean Conroy says in a note. Likewise, Bryan Garnier Research analysts say in a note that the pharma industry is left uncertain about an actual tariff risk given Trump's mixed remarks that drugmakers \"will come roaring back to the U.S., because if they don't, they got a big tax to pay.\" Novartis and Sanofi are up 0.6% and 0.3%, respectively. The U.K's AstraZeneca and GSK rose 1% and 1.6%, respectively. Swiss pharma giant Roche is down 2.3% after its multiple-sclerosis drug Ocrevus failed to meet its primary endpoint. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211331839.USD","03165","SNY","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0070302665.USD","IE00B2B36J28.USD","LU1829250122.USD","AZN","IE00BJJMRZ35.SGD","IE00BFXG1179.USD","LU2462157665.USD","IE0009355771.USD","GSK","IE00B4R5TH58.HKD","BK4585","LU0320765992.SGD","GSK.UK","LU0109394709.USD","LU2417539215.USD","IE0002141913.USD","LU2456880835.USD","BK4532","LU0320765489.SGD","BK4588","RHHBY","BK4007","NVS","BK4578","LU0208291251.USD","LU0889565916.HKD","LU2236285917.USD","BK4568"],"gpt_icon":1},{"id":"2524406442","title":"Big Pharma Avoids Worst-Case Tariff Scenario -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2524406442","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524406442?lang=en_us&edition=fundamental","pubTime":"2025-04-03 06:03","pubTimestamp":1743631380,"startTime":"0","endTime":"0","summary":"Drugmakers breathed a sigh of relief Wednesday after President Trump didn't announce pharmaceutical tariffs.Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce.Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won't be hit by any other tariff provisions, such as the 10% \"baseline\" tariff.President Trump had said he was going to impose pharmaceutical tariffs at some point-a move that could have affected branded medicines imported from countries like Ireland as well as the many generic drugs made in India.Shares of drugmakers in the U.S. and overseas varied in after-market trading, reflecting the lack of clarity.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051017.SGD","LU0058720904.USD","LU0466842654.USD","LU0795875169.SGD","03165","LU0234572021.USD","NVS","LU1066053197.SGD","LU0471298694.HKD","LU0320765489.SGD","RHHBY","LU2324357040.USD","BK4504","LU0203202063.USD","SG9999002232.USD","LU0114720955.EUR","GB00BDT5M118.USD","LU0792757196.USD","LU0208291251.USD","LU0225771236.USD","LU2237443622.USD","LU2361044949.HKD","PFE","IE00B42XCP33.USD","LU1162221912.USD","LU2461242641.AUD","LU1551013425.SGD","LU1674673691.USD","LU0170899867.USD","SG9999014898.SGD","LU1778281490.HKD","LU1883839398.USD","LU2237443465.HKD","LLY","IE00B19Z3B42.SGD","IE00BVYPNV92.GBP","LU0106261372.USD","IE00BJLML261.HKD","LU0943347566.SGD","LU2361045086.USD","LU2063271972.USD","LU0345770993.USD","LU2360106947.USD","IE000M9KFDE8.USD","JNJ","LU1989771016.USD","LU1868836914.USD","LU0471298777.SGD","LU0882574139.USD"],"gpt_icon":1},{"id":"2524304464","title":"Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening","url":"https://stock-news.laohu8.com/highlight/detail?id=2524304464","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524304464?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:06","pubTimestamp":1743591960,"startTime":"0","endTime":"0","summary":"Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to screening by enabling discreet self-collection. Quest also plans to make self-collection option available at its 2,000 patient service centers in the United States early next month, expanding access to screening. New solution follows company's launch of GTI self-collection option for several STIs and related conditions last fall. The solution is not FDA approved for at-home collection, and self-collection is not intended to replace a pelvic examination provided by a clinician. Patients should inform their healthcare provider if they suspect they are pregnant or if they have recently had symptoms of pelvic inflammatory disease . If the patient cannot self-collect a specimen, then collection should be performed in another healthcare setting, like a physician's office, where greater sup","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/quest-diagnostics-introduces-hpv-specimen-110600294.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quest-diagnostics-introduces-hpv-specimen-110600294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1854104046.USD","BK4007","RHHBY","BK4583","03165","BK4588","BK4567","LU1854103824.USD","BK4196","DGX","BK4585"],"gpt_icon":0},{"id":"2523181539","title":"Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2523181539","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523181539?lang=en_us&edition=fundamental","pubTime":"2025-03-31 17:31","pubTimestamp":1743413460,"startTime":"0","endTime":"0","summary":"Nvidia : Shares of the artificial-intelligence bellwether fell more than 3% in premarket trading. CoreWeave , the Nvidia-backed AI startup that went public last week, also fell before the bell.Tesla , Palantir : The auto and tech stocks were heavily traded premarket, both losing ground.Robinhood : Shares fell more than 5% ahead of the open, as bitcoin prices fell. The online brokerage gets a big chunk of its revenue from clients' cryptocurrency trades. Other crypto-focused stocks, including MicroStrategy  and Coinbase , dropped too.Renesas Electronics , Sumco , Tokyo Electron : The semiconductor companies were among the biggest losers in Japan, where the Nikkei 225 slumped. In Taiwan, Foxconn  and TSMC  dropped.Many of Europe's biggest stocks lost ground, including luxury companies LVMH  and Hermes , pharmaceutical companies Roche  and AstraZeneca  and global chip company ASML .This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/W","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"449cc4f57b8438a978a421912869bd9e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0354030511.USD","LU0345768740.USD","LU2242649171.HKD","NVDD","LU1815333072.USD","LVMUY","TSYW.SI","LU2168564149.EUR","NVDS","LU0077335932.USD","STRK","03165","LU1935042215.USD","LU1989764748.USD","NVDS.UK","LU2552382058.USD","NVD3.UK","RHHBY","NVDY","TSLL","LU1435385759.SGD","2NVD.UK","HOOD","NVDA","LU1127390331.HKD","NVD2.UK","NVDU","LU1852331112.SGD","SNVD.UK","AZN","LU0345774391.USD","3NVD.UK","NVIW.SI","NVDX","LU2065170008.USD","LU2456880835.USD","SGXZ23171101.USD","LU1037948897.HKD","LU0494093205.USD","LU0061474960.USD","SG9999014542.SGD","NVD"],"gpt_icon":1},{"id":"2522309020","title":"VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522309020","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522309020?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:31","pubTimestamp":1743078660,"startTime":"0","endTime":"0","summary":"Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing study, which is evaluating the safety and efficacy of the oral formulation of its experimental obesity drug VK2735. Data from this study is expected in the second half of 2025.This study has enrolled around 280 adults who are either obese or overweight and have at least one weight-related co-morbid condition. These patients have been evenly randomized to one of the six dosing arms of the drug or placebo. The study’s primary endpoint is the percent change in body weight from baseline after 13 weeks of treatment.In our opinion, this announcement marks a milestone for the company since the study initiation was declared in January. The rapid enrolment in the study suggests strong demand and interest in VK2735. This aligns with the market expansion for weight loss drugs, fueled by the success of Eli Lilly’s LLY Zepbound and Novo Nordisk’s NVO Wegovy. The quick recruitmen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vktx-finishes-enrolment-mid-stage-123100379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","LU0882574139.USD","LU1064131342.USD","IE00BVYPNW00.USD","LU1023059063.AUD","LU2602419157.SGD","LU1720051017.SGD","BK4139","LU0310800379.SGD","LU0965509283.SGD","SG9999018865.SGD","LU2491050154.USD","SG9999011175.SGD","LU0661504455.SGD","LU1732800096.USD","SGXZ81514606.USD","03165","LU0823416689.USD","BK4533","LU1037948541.HKD","LU0689472784.USD","RHHBY","AMGN","LU0122379950.USD","ABBV","LLY","LU2129689605.HKD","BK4532","LU0109391861.USD","LU1127390331.HKD","VKTX","LU0198837287.USD","SG9999013999.USD","LU0965509101.SGD","LU2087621335.USD","SG9999014898.SGD","IE00BK4W5L77.USD","LU1551013425.SGD","LU1974910355.USD","IE00B42XCP33.USD","LU0006306889.USD","SSI","LU0094547139.USD","LU1003077747.HKD","SGXZ57979304.SGD","SG9999018857.SGD","LU1988902786.USD","LU0820561818.USD","IE00B19Z3581.USD","LU1280957306.USD"],"gpt_icon":1},{"id":"2522984516","title":"Roche Poised For Growth Amid Obesity-Drug Ambitions -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2522984516","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522984516?lang=en_us&edition=fundamental","pubTime":"2025-03-26 16:49","pubTimestamp":1742978940,"startTime":"0","endTime":"0","summary":"0849 GMT - Roche is well positioned for growth in the medium-term on expedited obesity-drug ambitions, Baader Helvea analyst Abhishek Raval says in a note. The Swiss pharmaceutical company recently acquired a mid-stage weight-loss drug candidate from Danish biotech Zealand Pharma. The company also has a diversified portfolio of disease areas, Raval notes. \"With significant manufacturing and commercial might...the Swiss giant could become a serious contender in the obesity market,\" he says. Historically, Roche has usually been the market-leader in many of the disease areas it targets, the analyst says. Any progress in Roche's obesity pipeline could fuel the already solid share-price performance in recent months, he adds. Shares fall 0.9% to 302.90 Swiss francs. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","RHHBY","BK4007"],"gpt_icon":0},{"id":"2522016436","title":"The Zacks Analyst Blog Roche Holding, Comcast, Eaton Corp and National Presto Industries","url":"https://stock-news.laohu8.com/highlight/detail?id=2522016436","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522016436?lang=en_us&edition=fundamental","pubTime":"2025-03-25 15:16","pubTimestamp":1742886960,"startTime":"0","endTime":"0","summary":"Chicago, IL – March 25, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Roche Holding AG RHHBY, Comcast Corp. CMCSA, Eaton Corp. plc ETN and National Presto Industries, Inc. NPK.The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Pre-Markets Up on \"Narrower\" April 2nd Tariffs","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-analyst-blog-roche-holding-071600015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","BK4588","LU0985489474.SGD","LU1267930573.SGD","03165","LU1894683264.USD","LU0320765489.SGD","LU1988902786.USD","LU1861214812.USD","LU0942090050.USD","LU1861219969.SGD","LU0868494708.USD","LU0130102774.USD","LU0433182093.SGD","NPK","IE00B19Z9505.USD","LU0096362180.USD","IE00B894F039.SGD","IE00BZ1G4Q59.USD","BK4507","LU2506951792.HKD","RHHBY","BK4585","BK4187","BK4533","LU0708994859.HKD","ETN","LU0980610538.SGD","LU1059921491.USD","LU2294711713.HKD","BK4543","LU1489326972.SGD","LU1244550494.USD","LU0957791311.USD","IE00B2PGVK34.USD","LU1064131342.USD","IE00BGHQF417.EUR","IE00B19Z9P08.USD","LU1244550577.SGD","IE00B19Z8W00.USD","CMCSA","LU1244550221.USD","LU2249611893.SGD","LU1074936037.SGD","LU0208291251.USD","LU2357125470.USD","LU1150488135.SGD","LU1150488218.USD","LU0823414478.USD","BK4598"],"gpt_icon":0},{"id":"2521727420","title":"How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2521727420","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521727420?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:25","pubTimestamp":1742819100,"startTime":"0","endTime":"0","summary":"Shares of Sarepta Therapeutics SRPT plunged nearly 24% last week after the company reported the death of a patient following treatment with Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy .Sarepta reported that the patient’s death was due to acute liver failure, a known but rare risk associated with the use of Elevidys. This marks the first reported fatality linked to the gene therapy. Despite the incident, the company maintained its stance on the therapy’s positive benefit-risk profile, emphasizing that more than 800 patients have received Elevidys to date. Additionally, Sarepta noted that the patient had a recent CMV infection, which might have contributed to the adverse outcome, as CMV is known to cause liver damage.Apart from Elevidys, Sarepta has three other therapies in its commercial portfolio targeting the DMD patient population. Exondys 51 is the first approved disease-modifying therapy for DMD in the United States as well as the company’s first product to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/play-srpt-stock-patient-death-122500324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","BK4139","LU0889565916.HKD","IE0009355771.USD","IE00BJT1NW94.SGD","POST","IE00BJJMRZ35.SGD","LU0320765992.SGD","PTCT","BK4212","BK4007","SRPT","03165","BK4585","IE0002141913.USD","RHHBY"],"gpt_icon":0},{"id":"2520468110","title":"Novartis Reports Updated Positive Data From Phase III SMA Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2520468110","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520468110?lang=en_us&edition=fundamental","pubTime":"2025-03-20 21:34","pubTimestamp":1742477640,"startTime":"0","endTime":"0","summary":"NovartisNVS reported promising new safety and efficacy results from its phase III studies of investigational intrathecal onasemnogene abeparvovec  in a broad group of patients aged 2 to under 18 years with spinal muscular atrophy . OAV101 IT is an investigational, one-time gene therapy for patients with SMA.Additionally, in the phase IIIb STRENGTH study, treatment with OAV101 IT demonstrated stabilization of motor function over 52 weeks of follow-up in patients who had previously discontinued treatment with Spinraza  or Roche’s RHHBY Evrysdi .SMA, a rare, genetic neuromuscular disease caused by a lack of a functional SMN1 gene, results in the irreversible loss of motor neurons, affecting muscle functions, including breathing, swallowing and basic movement.Year to date, shares of Novartis have gained 14.6% compared with the industry’s 7.2% growth.Novartis presented these data at a recent medical conference held in Dallas, Texas. Per NVS, OAV101 IT is the first investigational gene repla","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-reports-updated-positive-data-133400414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B4R5TH58.HKD","BK4139","IE00BKVL7J92.USD","LU1066053197.SGD","IE0002141913.USD","III","LU1066051498.USD","BK4568","BK4134","BK4566","IE00B3T34201.USD","RHHBY","IE00BSNM7G36.USD","LU0208291251.USD","LU0109394709.USD","LU2089984988.USD","IE00BZ1G4Q59.USD","03165","NVS","BK4583","IE00BFTCPJ56.SGD","LU1839511570.USD","IE0002270589.USD","BK4532","IE0009355771.USD","BK4007","BK4578","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD","LU0320765489.SGD","LU1430594728.SGD","BK4588","IE00B7SZLL34.SGD","GILD","BK4585","LU0234570918.USD","LU0889565916.HKD","LU2468319806.SGD","LU0211331839.USD","LU1571399168.USD","LU2087621335.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD","LU0070302665.USD","LU0320765992.SGD","LU1585245621.USD","BK4550","IE00B19Z3581.USD","DVAX"],"gpt_icon":0},{"id":"2520160326","title":"SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2520160326","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520160326?lang=en_us&edition=fundamental","pubTime":"2025-03-20 01:38","pubTimestamp":1742405880,"startTime":"0","endTime":"0","summary":"Per the company, this patient died of acute liver failure. While acute liver injury is a known risk of Elevidys, this is the first time a death has been reported of anyone taking the therapy. However, Sarepta stated that the patient also had a recent CMV infection, which may have contributed to the outcome, as CMV can damage the liver.Sarepta has reported the event to health authorities, clinical study investigators and prescribing physicians. It intends to update Elevidys’ prescribing information accordingly. Despite the incident, the company maintains that the benefit-risk profile of its gene therapy remains positive, with over 800 patients treated in clinical studies or commercial use.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-nosedives-27-patient-death-173800583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0009355771.USD","BK4007","SRPT","CTMX","BK4585","03165","IE00BFTCPJ56.SGD","RHHBY","ANIP","IE00B2B36J28.USD","IE0002141913.USD","IE00BJT1NW94.SGD","BK4139","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2520095181","title":"Trump’s DEI Battle Goes Global as Swiss Drugs Group Roche (RHHBY) Terminates Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2520095181","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520095181?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:44","pubTimestamp":1742388291,"startTime":"0","endTime":"0","summary":"Investors in Swiss pharmaceuticals firm Roche ($RHHBY) were left nursing a headache today as its stock dropped on plans to scrap global diversity l...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/trumps-dei-battle-goes-global-as-swiss-drugs-group-roche-rhhby-terminates-targets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/trumps-dei-battle-goes-global-as-swiss-drugs-group-roche-rhhby-terminates-targets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4223","03165","BK4007","BK4194","RHHBY","DEI"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":127,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null},{"market":"US","date":"2024-02-01","symbol":"RHHBY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"","actualEps":null},{"date":"2023-07-27","symbol":"RHHBY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690444800000,"name":null,"time":"Pre-Market","dateTimestamp":1690430400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-02","recordDate":"2016-03-04","paymentDate":"2016-04-22","value":0.837655,"currency":"USD"},{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.125,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.75,"analysts":8,"updateTime":1746072000000}}}